TP53 and neoplasm: The resemblance of these two processes—dedifferentiation and epigenetic reprogramming—is highlighted by the effects of tumour suppressors such as p53 and cyclin dependent kinase inhibitors (e.g., p16) in blocking epigenetic reprogramming, while their inactivation increases the epigenetic reprogramming efficiency.